Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma
- Conditions
- Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)Follicular Lymphoma Patients (Phase IB)
- Interventions
- Registration Number
- NCT01582776
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Brief Summary
This study is to determine first the appropriate dose of lenalidomide to administer in combination with fixed doses of obinutuzumab in relapsed/refractory follicular lymphoma patients.
In a second step, this study aims to determine the efficacy of this combination in 3 separate populations: relapsed/refractory aggressive lymphoma (diffuse large B-cell lymphoma and mantle cell lymphoma: cohort 1), relapsed/refractory follicular lymphoma (cohort 2) and previously untreated follicular lymphoma (cohorts 3 and 4).
- Detailed Description
This study is an open label, multicenter study with two phases:
The Phase IB part of the study is a dose escalation study of lenalidomide (Revlimid) administered orally during on 3 weeks of every 28-day cycle, in combination with fixed doses of obinutuzumab (GA101) in relapsed/refractory follicular lymphoma patients.
The Phase II part of the study is an efficacy study of the association of the recommended dose of lenalidomide associated with GA101 in 2 separate populations of patients: relapsed/refractory aggressive lymphoma (diffuse large B-cell lymphoma and mantle cell lymphoma: cohort 1), relapsed/refractory follicular lymphoma (cohort 2) and previously untreated follicular lymphoma (cohorts 3 and 4). First, all patients will receive a combination of obinutuzumab and lenalidomide for a total of 6 cycles. Patients who achieve at least a partial response after 6 cycles will receive a maintenance treatment with obinutuzumab for 2 years and Lenalidomide for 1 year as tolerated, or until disease progression.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 317
- Phase IB only: Histologically documented CD20-positive follicular lymphoma (WHO grade 1, 2, or 3a) patients
- Phase II: Patients with either histologically documented CD20-positive Diffuse large-cell lymphoma or Mantle cell lymphoma (cohort 1) or follicular lymphoma, WHO grade 1, 2 or 3a (cohort 2-3-4)
- Phase IB and II:
- Relapsed/refractory NHL after ≥1 prior R-containing regimen with no curative option (cohort 2 only)
- Aged 18 years or more
- ECOG performance status 0, 1 or 2
- At least one bi-dimensionally measurable nodal or tumor lesion defined by CT scan as: greatest transverse diameter > 1.5 cm and a short axis ≥ 10mm
- Signed inform consent
- Life expectancy ≥ 3 months.
- All subjects must be able to understand and fulfill the lenalidomide Pregnancy Prevention Plan requirements (see in appendix)
- Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 2 months after discontinuation of all study treatments.
-
Previous treatment with obinutuzumab or lenalidomide
-
Known CD20 negative status at relapse/progression. Biopsy at relapse/progression is recommended but not mandatory
-
Central nervous system or meningeal involvement by lymphoma
-
Contraindication to any drug contained in the study treatment regimen
-
Known HIV or HTLV-1 infection, positive serology to HB surface antigen [HBsAg] or total HB core antibody [anti-HB-c]) and Hepatitis C (Hepatitis C virus [HCV] antibody)
-
Any serious active disease or co-morbid medical condition (such as New York Heart Association Class II or IV cardiac disease, severe arrhythmia, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision)
-
Any of the following laboratory abnormalities unless secondary to underlying lymphoma:
- Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).
- Platelet count < 100,000/mm3 (100 x 109/L) unless due to lymphoma for phase II part.
- Serum SGOT/AST or SGPT/ALT 3.0 x upper limit of normal (ULN) unless disease involvement.
- Serum total bilirubin > 2.0 mg/dL (34 μmol/L), except if disease related or in case of Gilbert syndrome
- Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of < 50 mL /min. For phase II part of the study, patients with calculated creatinine clearance between 30 and 50ml/min can be included and lenalidomide dose will be adjusted as follows (10mg once daily)
-
Prior history of malignancies other than lymphoma unless the subject has been free of the disease for ≥ 5 years
-
Any serious medical condition, laboratory abnormality (other than mentioned above), or psychiatric illness that would prevent the subject from signing the informed consent form.
-
Pregnant or lactating females.
-
Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide.
-
Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
-
Subjects with ≥ Grade 2 neuropathy.
-
Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy
-
Patients taking corticosteroids during 4 weeks before inclusion, unless administered at a dose equivalent to ≤ 10 mg/day prednisone (over these 4 weeks)
-
Prior history of Progressive Multifocal Leukoencephalopathy (PML)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Lenalidomide and GA101 Lenalidomide and GA101 Ga101 and lenalidomide
- Primary Outcome Measures
Name Time Method Phase I part: Determination of the recommended dose of lenalidomide in combination with fixed doses of GA101 28 days The determination of the recommended dose of lenalidomide in combination with fixed doses of GA101 will be performed by a dose escalation approach. Dose Limiting Toxicities (DLTs) observed during the administration of the first 2 cycles of the study will be listed for each escalation step.
Phase II part: Overall Response Rate (CR+CRu+PR) after 6 cycles 24 weeks Response rates at the end of treatment including maintenance will be expressed as percentages with their 95% Exact Clopper Pearson Confidence Interval limits
- Secondary Outcome Measures
Name Time Method Overall survival (OS) Up to 4.5 years Overall survival will be measured from the date of inclusion to the date of death from any cause.
Alive patients will be censored at their last date known to be aliveComplete response rate after induction 24 weeks Disease response evaluation after 6 cycles will be used to determine the Complete Response Rate. Response after 6 cycles will be assessed only if patient completes induction phase. Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999 and 2007)).
Event Free survival Up to 4.5 years Event-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause.
Response duration Up to 4.5 years Patients alive and free of progression will be censored at their last follow-up date
Complete response rate after 3 cycles 12 weeks Disease response evaluation after 3 cycles will be used to determine the Complete Response Rate.
Response after 3 cycles will be assessed at the end of completion of the 3 cycles if patient received all 3 cycles or at withdrawal. Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999 and 2007).Progression free survival Up to 4.5 years Progression-Free Survival will be measured according to the Cheson 2007 criteria. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.
Response rate at the end of maintenance treatment 2.5 years Response rates will be evaluated at the end of maintenance phase for patients who achieve a CR/PR after induction treatment and received at least one dose of maintenance. Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 2007)). Patient without response assessment after maintenance treatment (due to whatever reason) will be considered as non-responder.
Trial Locations
- Locations (25)
CHU Brabois
🇫🇷Nancy, France
CHU Hôtel Dieu
🇫🇷Nantes, France
Institut Bergonié
🇫🇷Bordeaux, France
CHU de Dijon
🇫🇷Dijon, France
CHRU de Lille
🇫🇷Lille, France
Institut Paoli Calmette
🇫🇷Marseille, France
AZ Groeninge - Campus Maria's Voorzienigheid
🇧🇪Kortrijk, Belgium
ZNA Stuivenberg
🇧🇪Antwerpen, Belgium
CHU de Liège
🇧🇪Liège, Belgium
Université Catholique de Louvain Mont Godinne
🇧🇪Yvoir, Belgium
CHU de Grenoble
🇫🇷Grenoble, France
Centre Léon Bérard
🇫🇷Lyon, France
CHU St Eloi
🇫🇷Montpellier, France
CH Lyon Sud
🇫🇷Pierre Bénite, France
institut Jules Bordet
🇧🇪Bruxelles, Belgium
Université Catholique de Louvain Saint Luc
🇧🇪Bruxelles, Belgium
A.Z. Sint Jan AV
🇧🇪Bruges, Belgium
CHU d'Amiens
🇫🇷Amiens, France
Institut d'Hématologie de Basse Normandie
🇫🇷Caen, France
CHU d'Estaing
🇫🇷Clermont-Ferrand, France
Hôpital Henri Mondor
🇫🇷Créteil, France
Hôpital St Louis
🇫🇷Paris, France
CHU Pontchaillou
🇫🇷Rennes, France
Centre François Magendie
🇫🇷Pessac, France
Centre henri Becquerel
🇫🇷Rouen, France